Connecting The Dots Between Discovery, Development, And mAb Manufacturing Efficiency

Assessing the manufacturability of a molecule can be a make-it-or-break-it exercise for an early-stage biopharma, so it’s best to conduct CMC assessments early and often. In this segment of the Bioprocess Online Live Event _Overcoming Platform Inefficiencies In mAb Manufacturing_, AltruBio Chief Technical Officer Gene Lee and EQRx Sr. Director of Manufacturing Sciences & Technology Avril Vermunt discuss the inextricable links between early-stage discovery and development and the ultimate goal of manufacturing mAbs for clinical trials and beyond.